PE20180696A1 - Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas - Google Patents
Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinasInfo
- Publication number
- PE20180696A1 PE20180696A1 PE2018000223A PE2018000223A PE20180696A1 PE 20180696 A1 PE20180696 A1 PE 20180696A1 PE 2018000223 A PE2018000223 A PE 2018000223A PE 2018000223 A PE2018000223 A PE 2018000223A PE 20180696 A1 PE20180696 A1 PE 20180696A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- inhibitor
- tetrahydropyridines
- trifluoro
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Esta referido al uso combinado de un inhibidor de BACE1 (enzima beta-secretasa 1) de formula I; en donde Ar es fenilo, piridilo, pirimidilo, entre otros; R1 es alquilo C1-C3 o fluoroalquilo C1-C3; R2 es H, halogeno, fluoroalquilo C1-C3 o alquilo C1-C3; R3 es alquilo C1-C3; y un compuesto util en la inmunoterapia de Tau activa o pasiva, un compuesto util en la inmunoterapia de peptido Abeta activa o pasiva, un antagonista de receptor de NMDA, un inhibidor de acetilcolina esterasa, un antiepileptico, un farmaco antiinflamatorio, un inhibidor de la agregacion de Tau o un SSRI para el tratamiento de trastornos neurodegenerativos o cognitivos, tal como enfermedad de Alzheimer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201500456 | 2015-08-10 | ||
DKPA201500707 | 2015-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180696A1 true PE20180696A1 (es) | 2018-04-23 |
Family
ID=56799425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000223A PE20180696A1 (es) | 2015-08-10 | 2016-08-09 | Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas |
Country Status (26)
Country | Link |
---|---|
US (1) | US10004738B2 (es) |
EP (1) | EP3334461A1 (es) |
JP (1) | JP2018529647A (es) |
KR (1) | KR20180035843A (es) |
CN (1) | CN107921138A (es) |
AR (1) | AR105656A1 (es) |
AU (1) | AU2016305260A1 (es) |
BR (1) | BR112017007306A2 (es) |
CA (1) | CA2993623A1 (es) |
CL (1) | CL2018000339A1 (es) |
CO (1) | CO2018000711A2 (es) |
CR (1) | CR20180093A (es) |
DO (1) | DOP2018000039A (es) |
EA (1) | EA201890257A1 (es) |
EC (1) | ECSP18010534A (es) |
HK (1) | HK1254354A1 (es) |
IL (1) | IL257072A (es) |
MA (1) | MA42611A (es) |
MX (1) | MX2018001636A (es) |
PE (1) | PE20180696A1 (es) |
PH (1) | PH12018500300A1 (es) |
RU (1) | RU2018104867A (es) |
SV (1) | SV2018005628A (es) |
TN (1) | TN2018000041A1 (es) |
TW (1) | TW201717948A (es) |
WO (1) | WO2017025532A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
MX2018001699A (es) | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
MXPA04007838A (es) | 2002-02-12 | 2004-10-15 | Smithkline Beecham Corp | Derivados de nicotamida utiles como inhibidores p38. |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
SG185651A1 (en) | 2010-06-09 | 2012-12-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
MX2013008111A (es) | 2011-01-12 | 2013-10-30 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos. |
EA024059B1 (ru) | 2011-01-13 | 2016-08-31 | Новартис Аг | Гетероциклические производные и их применение в лечении неврологических расстройств |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
US8987255B2 (en) | 2011-06-07 | 2015-03-24 | Hoffmann-La Roche Inc. | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
JP2015531401A (ja) * | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノン骨格を有するpde9i |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
BR112014023384A8 (pt) | 2012-03-20 | 2018-01-16 | R Artis Dean | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. |
WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
WO2014134341A1 (en) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
MA39225A1 (fr) | 2014-02-19 | 2017-04-28 | H Lundbeck As | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MX2018001699A (es) | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
-
2016
- 2016-08-04 TW TW105124755A patent/TW201717948A/zh unknown
- 2016-08-08 US US15/231,182 patent/US10004738B2/en not_active Expired - Fee Related
- 2016-08-09 EA EA201890257A patent/EA201890257A1/ru unknown
- 2016-08-09 CA CA2993623A patent/CA2993623A1/en not_active Abandoned
- 2016-08-09 MA MA042611A patent/MA42611A/fr unknown
- 2016-08-09 TN TNP/2018/000041A patent/TN2018000041A1/en unknown
- 2016-08-09 MX MX2018001636A patent/MX2018001636A/es unknown
- 2016-08-09 JP JP2018506913A patent/JP2018529647A/ja active Pending
- 2016-08-09 CN CN201680045247.2A patent/CN107921138A/zh active Pending
- 2016-08-09 PE PE2018000223A patent/PE20180696A1/es not_active Application Discontinuation
- 2016-08-09 KR KR1020187005381A patent/KR20180035843A/ko unknown
- 2016-08-09 RU RU2018104867A patent/RU2018104867A/ru not_active Application Discontinuation
- 2016-08-09 CR CR20180093A patent/CR20180093A/es unknown
- 2016-08-09 AR ARP160102441A patent/AR105656A1/es unknown
- 2016-08-09 BR BR112017007306A patent/BR112017007306A2/pt not_active Application Discontinuation
- 2016-08-09 AU AU2016305260A patent/AU2016305260A1/en not_active Abandoned
- 2016-08-09 WO PCT/EP2016/068947 patent/WO2017025532A1/en active Application Filing
- 2016-08-09 EP EP16756631.4A patent/EP3334461A1/en not_active Withdrawn
-
2018
- 2018-01-22 IL IL257072A patent/IL257072A/en unknown
- 2018-01-25 CO CONC2018/0000711A patent/CO2018000711A2/es unknown
- 2018-02-06 CL CL2018000339A patent/CL2018000339A1/es unknown
- 2018-02-07 SV SV2018005628A patent/SV2018005628A/es unknown
- 2018-02-08 DO DO2018000039A patent/DOP2018000039A/es unknown
- 2018-02-09 PH PH12018500300A patent/PH12018500300A1/en unknown
- 2018-02-09 EC ECIEPI201810534A patent/ECSP18010534A/es unknown
- 2018-10-19 HK HK18113430.1A patent/HK1254354A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1254354A1 (zh) | 2019-07-19 |
KR20180035843A (ko) | 2018-04-06 |
CR20180093A (es) | 2018-06-05 |
AR105656A1 (es) | 2017-10-25 |
WO2017025532A1 (en) | 2017-02-16 |
CN107921138A (zh) | 2018-04-17 |
PH12018500300A1 (en) | 2018-08-29 |
US10004738B2 (en) | 2018-06-26 |
AU2016305260A1 (en) | 2018-02-15 |
TN2018000041A1 (en) | 2019-07-08 |
ECSP18010534A (es) | 2018-04-30 |
MA42611A (fr) | 2018-06-20 |
MX2018001636A (es) | 2018-05-07 |
CA2993623A1 (en) | 2017-02-16 |
US20170042895A1 (en) | 2017-02-16 |
EA201890257A1 (ru) | 2018-07-31 |
RU2018104867A (ru) | 2019-09-12 |
DOP2018000039A (es) | 2018-04-30 |
CL2018000339A1 (es) | 2018-07-06 |
EP3334461A1 (en) | 2018-06-20 |
SV2018005628A (es) | 2018-04-19 |
CO2018000711A2 (es) | 2018-05-10 |
IL257072A (en) | 2018-03-29 |
JP2018529647A (ja) | 2018-10-11 |
TW201717948A (zh) | 2017-06-01 |
BR112017007306A2 (pt) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500529A1 (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
PH12016501355B1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
PE20180696A1 (es) | Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas | |
PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
ECSP13012967A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
WO2012101065A3 (en) | Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors | |
CL2012001139A1 (es) | Compuestos derivados de imidazo[1.2-b]piridazina, inhibidores de pde10; composicion farmaceutica; procedimiento de preparacion; util para el tratamiento o prevencion de un trastorno del snc, tales como trastornos psicoticos, de ansiedad, del movimiento, del humor, neurodegenerativos, metabolicos y del dolor, entre otros. | |
CO7131369A2 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
TN2016000491A1 (en) | Carboxamide derivatives. | |
PH12017501668A1 (en) | Bace1 inhibitors | |
MX2016013561A (es) | Activadores de herg policiclicos. | |
AR107752A1 (es) | Inhibidores de bace1 | |
MA41158A (fr) | Composition pharmaceutique comprenant un composé d'amide hétérocyclique aromatique contenat de l'azote bicyclique en tant que principe actif | |
EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний | |
NZ743308A (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
PL420629A1 (pl) | Nowe pochodne karbaminianów oraz ich zastosowanie | |
EA202191885A2 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
MY170491A (en) | Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |